AbbVie (NYSE: ABBV) today announced that the European Commission (EC) granted marketing authorization to RINVOQ� (upadacitinib; 15 mg, once daily) for the treatment of giant cell arteritis (GCA) in ...

Pharmacovigilance evolves with technology, employing active surveillance to detect drug-related issues and ensure safety in an increasingly complex landscape.

RINVOQ is the first and only oral Janus kinase (JAK) inhibitor approved in the European Union (EU) to treat adult patients with giant cell arteritis (GCA) The approval ...

Judge Sean D. Jordan of the U.S. District Court for the Eastern District of Texas ruled that the Food and Drug Administration ...

KalVista Pharmaceuticals, Inc. today announced that its wholly-owned subsidiary, KalVista Pharmaceuticals, Ltd., has licensed commercialization rights in Japan to Kaken Pharmaceutical, Co., Ltd. (JPX: ...

Private health insurers may soon be able to offer rebates for seven complementary therapies previously prohibited. This ...

Consumer groups, doctors, state advocates offer advice on what you can do when insurance denies you coverage or bills don't make sense.

Throughout the course of multiple sclerosis, gradually progressive neurologic impairment can occur, which has been called ...

Starting April 15, Blue Cross Blue Shield (BCBS) patients in five states will need prior authorization for in-clinic asthma ...

Psychiatric Services to Residents Civilly Committed ...